ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Allogeneic Invariant Natural Killer T-cells agenT-797

Also written as “agenT-797” and “Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)”.

Its studies are mostly in Respiratory Distress Syndrome · Pneumonia · Neoplasms · Multiple Myeloma, led by 3 companies.

Drug pageAllogeneic Invariant Natural Killer T-cells agenT-797: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Oct 6, 20205 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agenus30 open or runningphase 1since Oct 6, 2020Oct 6, 2020none ahead
ImmunityBioits history only10 open or runningphase 2since Mar 13, 2026Mar 13, 2026none ahead
MiNK Therapeuticsits history only11 open or runningphase 2since May 22, 2026May 22, 2026Jun 2027phase 2 · NCT07615010

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Agenus only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2020First study: phase 1 study in Respiratory Distress SyndromeFirst studyNCT04582201 · 20 enrolled · United States
  2. Feb 3, 2021Phase 1 study in Multiple MyelomaNCT04754100 · 13 enrolled · United States
  3. Oct 12, 2021Phase 1 study in NeoplasmsNCT05108623 · 34 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Agenus leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05108623Neoplasms · United States1CompletedJan 2, 202434
NCT04754100Multiple Myeloma · United States1CompletedJan 13, 202313
NCT04582201Respiratory Distress Syndrome · United States1CompletedApr 23, 202320

How it is read

Names in the registry

  • “agenT-797”, 4 entries
  • “Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.